Information  X 
Enter a valid email address

Renalytix AI PLC (RENX)

  Print      Mail a friend

Tuesday 20 August, 2019

Renalytix AI PLC

Notice of Results

RNS Number : 5371J
Renalytix AI PLC
20 August 2019
 

Renalytix AI plc

("RenalytixAI" or the "Company")

 

Notice of results

Investor briefing

 

Renalytix AI plc (AIM: RENX), a developer of artificial intelligence clinical in vitro diagnostics for kidney disease, announces that it will release its preliminary results for the year ended 30 June 2019 on Tuesday, 3 September 2019.

 

Analyst briefing

An analyst briefing will take place at 1pm on Tuesday, 3 September 2019. If you would like to register, please contact Walbrook PR on 020 7933 8780 or email [email protected] 

 

Investor briefing

A briefing open to all investors will take place on Tuesday, 3 September 2019 at the Brand Exchange, 3 Birchin Lane, London EC3V 9BW from 5.15pm for a 5.30pm start and will be followed by light refreshments. If you would like to register, please contact Walbrook PR on 020 7933 8780 or email [email protected]

 

 

For further information, please contact:

 

Renalytix AI plc 

www.renalytixai.com

James McCullough, CEO

Via Walbrook PR



Stifel (Nominated Adviser & Joint Broker)

Tel: 020 7710 7600

Alex Price / Jonathan Senior / Ben Maddison




N+1 Singer (Joint Broker)

Tel: 020 7496 3000

Aubrey Powell / James White / George Tzimas (Corporate Finance)


Tom Salvesen / Mia Gardner (Corporate Broking)








Walbrook PR Limited

Tel: 020 7933 8780 or [email protected]

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303

 

About Kidney Disease 

Kidney disease is now recognised as a public health epidemic affecting over 850 million people globally. In the United States alone, over 40 million people are classified as having chronic kidney disease, with nearly 50 percent of individuals with advanced (Stage IV) disease unaware of the severity of their reduced kidney function. As a result, many patients progress to kidney failure in an unplanned manner, ending up having dialysis in the emergency room without ever seeing a clinical specialist, such as a nephrologist. Every day 13 patients die in the United States while waiting for a kidney transplant.

 

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NORSFWFLUFUSEIA

a d v e r t i s e m e n t